Open AccessSuccessful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
Author(s) -
Chariclia Loupa,
Elissavet Lykoudi,
Evangelia Meimeti,
Ioannis Moisoglou,
Eleftherios D Voyatzoglou,
Sophia Kalantzi,
Ekaterini Konsta
Publication year - 2020
Publication title -
medicinski arhiv
Language(s) - English
Resource type - Journals
eISSN - 1986-5961
pISSN - 0350-199X
DOI - 10.5455/medarh.2020.74.243-245
Subject(s) - dalbavancin , medicine , linezolid , tigecycline , osteomyelitis , enterococcus faecium , surgery , diabetic foot , antibiotics , diabetes mellitus , staphylococcus aureus , vancomycin , endocrinology , biology , bacteria , microbiology and biotechnology , genetics
Dalbavancin is a new antibiotic against multi-drug resistant Gram (+) bacteria. Dalbavancin has an extremely long half-life. Current indication is skin and soft tissue infections (ABSSSI), but researchers have successfully administered it off-label to osteomyelitis (OM) patients.